American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6400)
  2. Solid Tumor Oncology Division (5538)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1637)
  6. Epidemiology and Biostatistics (1495)
  7. GSK Faculty (1389)
  8. Population Sciences Research Program (1379)
  9. Gastrointestinal Oncology Service (1354)
  10. Hematologic Malignancies, Division of (1281)
Search Within
Formats
  1. Meeting Abstract (6334)
  2. Journal Article (2582)
  3. Editorial (76)
  4. Review (68)
  5. Guidelines (55)
  6. Correspondence (49)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6400)
  2. Solid Tumor Oncology Division (5538)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1637)
  6. Epidemiology and Biostatistics (1495)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (279)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8697)
  2. JCO Precision Oncology (171)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (8)

More Publications

Results (9171)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Machine learning for automated interpretation of fluorodeoxyglucose-positron emission tomography scans in lymphoma
    Editorial

    Schòˆder, H.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Pediatric leukemia roadmaps are a guide for positive metastatic bone sarcoma trials
    Journal Article

    Reed, D. R.; Tulpule, A.; Metts, J.; Trucco, M.; Robertson-Tessi, M.; O'Donohue, T. J.; Iglesias-Cardenas, F.; Isakoff, M. S.; Mauguen, A.; Shukla, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Dose/exposure relationship of exercise and distant recurrence in primary breast cancer
    Journal Article

    Soldato, D.; Michiels, S.; Havas, J.; Di Meglio, A.; Pagliuca, M.; Franzoi, M. A.; Pistilli, B.; Iyengar, N. M.; Cottu, P.; Lerebours, F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC
    Meeting Abstract

    Fujiwara, Y.; Burns, T. F.; Dragnev, K. H.; Murciano-Goroff, Y. R.; Lee, D. H.; Hollebecque, A.; Koyama, T.; Cassier, P. A.; Italiano, A.; Heist, R. S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC
    Meeting Abstract

    Nishio, M.; Negrao, M. V.; Arbour, K. C.; Burns, T. F.; Cappuzzo, F.; Dingemans, A. M. C.; Girard, N.; Gronberg, B. H.; Hochmair, M.; Leal, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations
    Meeting Abstract

    Nishio, M.; Yu, H. A.; Besse, B.; Cheng, Y.; Tan, D. S. W.; Wei, L.; Wacheck, V.; Heymach, J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma
    Meeting Abstract

    Kudo, M.; Chan, S. L.; Sangro, B.; Erinjeri, J. P.; Qin, S.; Ren, Z.; Arai, Y.; Breder, V. V.; Lin, S. M.; Peron, J. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Health disparity viewed from public historic cancer mortality data in the US: Advocacy for gastrointestinal cancers, for tailored prevention measures, and for inter-agency population data harmonization
    Meeting Abstract

    Zhang, T.; Hung, T.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Retrieval-augmented large language models for clinical trial screening
    Meeting Abstract

    He, J.; Gai, S.; Ho, S. X.; Chua, S. L.; Oo, V.; Zaw, M. W. W.; Tan, D. S. W.; Tan, R.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Patient-reported outcomes in patients with advanced urothelial cancer who are ineligible for cisplatin and treated with first-line enfortumab vedotin alone or with pembrolizumab
    Journal Article

    Milowsky, M. I.; O'Donnell, P. H.; Hoimes, C. J.; Petrylak, D. P.; Flaig, T. W.; Moon, H. H.; Friedlander, T. W.; Mar, N.; McKay, R. R.; Srinivas, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save